EP Patent

EP2588086B1 — Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.

Assigned to Novartis AG · Expires 2018-09-12 · 8y expired

What this patent protects

Patent listed against osilodrostat-phosphate.

Drugs covered by this patent

osilodrostat-phosphate (OSILODROSTAT PHOSPHATE)

Patent Metadata

Patent number: EP2588086B1
Jurisdiction: EP
Classification: —
Expires: 2018-09-12
Drug substance claim: No
Drug product claim: No
Assignee: Novartis AG
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.